Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Long-Term Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh Cardiovascular Risk PatienTs With Hypertriglyceridemia (STRENGTH)

Trial Profile

A Long-Term Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh Cardiovascular Risk PatienTs With Hypertriglyceridemia (STRENGTH)

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 07 Dec 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Omega-3 carboxylic acids (Primary) ; HMG-CoA reductase inhibitors
  • Indications Cardiovascular disorders; Hypertriglyceridaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms STRENGTH
  • Sponsors AstraZeneca
  • Most Recent Events

    • 15 Nov 2020 Primary endpoint (The primary outcome measure is the time to the first occurrence of any component of the composite of MACE.) has not been met.
    • 15 Nov 2020 Results published in the JAMA: the Journal of the American Medical Association.
    • 30 Jul 2020 This trial has been completed in Belgium, according to European Clinical Trials Database record.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top